BeiGene, Ltd.

NasdaqGS:BGNE Rapporto sulle azioni

Cap. di mercato: US$20.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BeiGene Gestione

Gestione criteri di controllo 1/4

BeiGene's Il CEO è John Oyler, nominato in Jan2010, e ha un mandato di 14.58 anni. la retribuzione annua totale è $ 18.93M, composta da 4.6% di stipendio e 95.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 3.41% delle azioni della società, per un valore di $ 695.59M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 4.6 anni.

Informazioni chiave

John Oyler

Amministratore delegato

US$18.9m

Compenso totale

Percentuale dello stipendio del CEO4.6%
Mandato del CEO14.6yrs
Proprietà del CEO3.4%
Durata media del management1.8yrs
Durata media del Consiglio di amministrazione4.6yrs

Aggiornamenti recenti sulla gestione

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Recent updates

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31
BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Oct 16
Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Jul 11
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?

Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Jun 19
Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt

Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

Apr 17
Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)

A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Mar 24
A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)

Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?

Dec 07
Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di John Oyler rispetto agli utili di BeiGene?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$524m

Mar 31 2024n/an/a

-US$784m

Dec 31 2023US$19mUS$871k

-US$882m

Sep 30 2023n/an/a

-US$959m

Jun 30 2023n/an/a

-US$2b

Mar 31 2023n/an/a

-US$2b

Dec 31 2022US$18mUS$800k

-US$2b

Sep 30 2022n/an/a

-US$2b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$2b

Dec 31 2021US$17mUS$740k

-US$1b

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$14mUS$696k

-US$2b

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$1b

Mar 31 2020n/an/a

-US$1b

Dec 31 2019US$13mUS$675k

-US$949m

Sep 30 2019n/an/a

-US$829m

Jun 30 2019n/an/a

-US$665m

Mar 31 2019n/an/a

-US$737m

Dec 31 2018US$28mUS$650k

-US$674m

Sep 30 2018n/an/a

-US$505m

Jun 30 2018n/an/a

-US$243m

Mar 31 2018n/an/a

-US$147m

Dec 31 2017US$10mUS$515k

-US$93m

Compensazione vs Mercato: La retribuzione totale di John ($USD 18.93M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 13.21M ).

Compensazione vs guadagni: La retribuzione di John è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

John Oyler (56 yo)

14.6yrs

Mandato

US$18,925,730

Compensazione

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
John Oyler
Co-Founder14.6yrsUS$18.93m3.41%
$ 701.8m
Xiaobin Wu
President & COO6.3yrsUS$11.00m0.065%
$ 13.5m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder14.6yrsUS$4.42m0.83%
$ 170.3m
Chan Lee
General Counsel & Senior VP2.1yrsUS$4.05m0.018%
$ 3.8m
Wang Lai
Global Head of R&Dno dataUS$7.32m0.13%
$ 26.6m
Julia Wang
Executive Officerless than a yearUS$6.07m0.031%
$ 6.4m
Aaron Rosenberg
CFO & Principal Financial Officerless than a yearNessun datoNessun dato
Titus Ball
VP & Chief Accounting Officerless than a yearNessun datoNessun dato
Liza Heapes
Head of Investor Relationsno dataNessun datoNessun dato
Yang Ji
Chief Compliance Officerless than a yearNessun datoNessun dato
Yan Qi
Senior VP & Head of Public Affairs - Greater China3.6yrsNessun datoNessun dato
Jason Radford
Senior Vice President of Strategy & Corporate Development1.5yrsNessun datoNessun dato

1.8yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di BGNE non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
John Oyler
Co-Founder13.8yrsUS$18.93m3.41%
$ 701.8m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder8.5yrsUS$4.42m0.83%
$ 170.3m
Steven Young
Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board3.3yrsNessun datoNessun dato
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee9.3yrsUS$481.92k0.0034%
$ 696.6k
Donald Glazer
Independent Non-Executive Director11.5yrsUS$480.80k0.20%
$ 40.4m
Corazon Sanders
Independent Non-Executive Director & Member of Scientific Advisory Committee4yrsUS$501.55k0.0022%
$ 447.2k
Anthony Hooper
Independent Non-Executive Director4.6yrsUS$513.15k0.0027%
$ 558.5k
Alessandro Riva
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director2.5yrsUS$491.67k0.0022%
$ 443.1k
Olivier Brandicourt
Independent Non-Executive Directorless than a yearNessun dato0%
$ 0
Ranjeev Krishana
Independent Lead Director9.8yrsUS$487.05k0.0034%
$ 696.6k
Margaret Han Dugan
Member of Scientific Advisory Board & Independent Non-Executive Director2.5yrsUS$510.55k0.0022%
$ 443.1k

4.6yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BGNE sono considerati esperti (durata media dell'incarico 4.6 anni).